According to the Punch NG, a Nigerian newspaper, this information was provided on Monday during a news conference in Abuja by Prof. Mojisola Adeyeye, Director General of Nigeria’s drug regulatory body, NAFDAC.
The R21 malaria vaccine produced by the Serum Institute of India has received approval from the National Agency for Food and Drug Administration and Control.
She stated that before the market authorization will begin making further arrangements with the National Primary Health Care Development Agency, the nation anticipates receiving at least 100,000 doses of the vaccine in contributions shortly.
